Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics.
about
Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistanceAn initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients.Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.Higher serum caffeine in smokers with schizophrenia compared to smoking controls.Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.Recovery of behavioral changes and compromised white matter in C57BL/6 mice exposed to cuprizone: effects of antipsychotic drugsAnalysis of Adverse Drug Reactions of Atypical Antipsychotic Drugs in Psychiatry OPDAripiprazole: the evidence of its therapeutic impact in schizophreniaNeural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.Sertindole: efficacy and safety in schizophrenia.Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders.Paliperidone: a new extended-release oral atypical antipsychotic.Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled studyEfficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia.Aripiprazole (abilify) and tardive dyskinesia.Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.Sleep in psychiatric disorders: where are we now?Quetiapine: novel uses in the treatment of depressive and anxiety disorders.Metabonomic studies of schizophrenia and psychotropic medications: focus on alterations in CNS energy homeostasis.Management of schizophrenia: clinical experience with asenapine.Effect of a system-oriented intervention on compliance problems in schizophrenia: a pragmatic controlled trial.The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.Emerging role of sertindole in the management of schizophrenia.Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia.Costs of schizophrenia during 5 years.Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome.Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior.A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.Addressing the limitations of the CATIE study
P2860
Q27323282-43DA9A30-188F-4CC7-8460-F0218B1B22DBQ30491026-AE372E70-E1B2-45AD-A5B4-EB96000A0760Q33755676-F5B5AEC0-6096-4814-B971-41F29AC21316Q33912741-1670FC40-7B8F-4422-B8FA-27C63C770FA1Q34103173-868B7135-CDD2-4110-843C-32748EDE2552Q35087719-FAA69E4A-E32A-4665-AF65-3414F9355969Q35732364-0B8D534F-4AF6-43A9-AD64-5F43FA3396F8Q35876413-4A058A29-9502-419A-9681-A915C56C57A4Q36061639-CBB6E589-8AF4-46E6-B798-00D5C924D1A7Q36573915-24979E50-EF8C-46DB-9921-F4A8797E854EQ36860053-1131E64A-5DCF-4DCE-A7BA-0A0440CC8090Q36904901-AB17BF18-FC65-438B-9E6E-2D6809FD7DEAQ36967269-204BB002-74CE-4B7B-84BA-BC74FB45EBE9Q37030153-3500511E-1C78-440F-A38F-F433015AFACCQ37299902-6B5152B2-768B-4AA5-8D4B-B7BD11E0EE8EQ37313562-14CC3B87-5627-4040-9962-0EDAA3DF746BQ37422493-2F15A16E-7A95-4ADC-8FFD-BD98025E4AB1Q37707292-2C60DF2D-5E10-492E-A404-4E19D5CB8A79Q37779583-CA7B640A-AADF-444A-BB8F-B609995A0B05Q37783300-A4A7BD4F-80C5-4CCE-9B75-3AD7946BE4DBQ37810163-BCEBCF0A-E6F7-4E15-BB43-2DFB004E71FBQ38093729-95C48253-6925-4C0A-A4C3-4144135A190AQ40785183-57BAED54-8BCE-4152-B975-B606CFCFCCC6Q41879506-9257EC48-BCB3-47FE-B2B3-CFCE2F751461Q42168997-4D451D5B-14C6-4790-A8BC-84CE488073D0Q42427678-D1AFDE81-969B-40E5-B0EE-9415B669DFA5Q46038979-A8FEA2B0-59DC-49BC-B1E2-BCDAB6105E45Q46937644-7D38E921-6805-427F-AC2C-474FB9532BB7Q46937654-7246AAF8-26C2-4FF0-9BDA-8044891B20C0Q48354605-3B52B660-EE99-48E8-BB0A-D9E2314AA4C1Q48381074-A3BFFDD4-7A18-4EB5-8E38-B3F5205AED80Q48423410-98F96D12-5CD3-4653-A483-6413628939B8Q57738653-D8ADD9E6-5812-4053-9345-EAD9036D65A6
P2860
Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Current therapy issues and unm ...... new generation antipsychotics.
@ast
Current therapy issues and unm ...... new generation antipsychotics.
@en
type
label
Current therapy issues and unm ...... new generation antipsychotics.
@ast
Current therapy issues and unm ...... new generation antipsychotics.
@en
prefLabel
Current therapy issues and unm ...... new generation antipsychotics.
@ast
Current therapy issues and unm ...... new generation antipsychotics.
@en
P1476
Current therapy issues and unm ...... new generation antipsychotics.
@en
P2093
Henrik Lublin
Jonas Eberhard
P304
P356
10.1097/00004850-200507000-00001
P577
2005-07-01T00:00:00Z